When the Immune System Gets Outmaneuvered
Immunotherapy has changed cancer treatment. Drugs that unleash the immune system to fight cancer have helped patients who had run out of other options.
But for many patients, these drugs simply stop working. Or they never work at all.
The Tumor's Clever Defense Strategy
Tumors are not passive targets. They actively reshape the environment around them to protect themselves from both the immune system and from treatments.
One of the most important ways they do this involves energy. To grow quickly, tumor cells burn sugar at a furious rate — even when oxygen is available — a process called aerobic glycolysis (or the Warburg effect, named after the scientist who first described it). This rapid sugar burning generates enormous amounts of lactate, a waste product that spills out of tumor cells and fills the surrounding tissue.
Old Thinking vs. New Understanding
Scientists used to think lactate was just metabolic exhaust — a messy byproduct of fast cell growth that had no further role.
But here's the twist: lactate turns out to be a signal. A powerful one.
Lactate attaches to proteins inside cells through a process called lactylation (think of it as a chemical tag, like a sticky note placed on a protein to change its behavior). These lactylation tags can switch genes on or off — meaning lactate is not just waste, it's a message that rewrites how cells behave.
How Lactate Shuts Down Your Immune Cells
Think of tumor-infiltrating immune cells as security guards trying to do their job, but the building's management keeps reassigning them to desk work.
Lactate-driven lactylation does several things to undermine the immune attack. It pushes macrophages (a type of immune cell that normally fights cancer) into a mode where they protect the tumor instead of attacking it. It boosts the activity of regulatory T cells (immune cells that dampen immune responses — helpful in normal circumstances, harmful in cancer). And it exhausts CD8+ T cells — the frontline killer cells that directly destroy cancer.
At the same time, lactylation helps cancer cells repair their own DNA damage faster, making them harder to kill with chemotherapy or radiation. It also stabilizes a protein called PD-L1 (the very target that many immunotherapy drugs try to block), making those drugs less effective.
What the Review Covered
This was a comprehensive scientific review, not a single clinical trial. Researchers synthesized evidence from laboratory studies — cancer cell lines, animal models, and patient-derived tumor samples — to piece together how the glycolysis-lactylation axis operates across different cancer types.
It's important to note that this research is still largely preclinical, meaning it has not yet been tested in large-scale human trials.
The picture that emerges is of a tightly connected system. Tumors burn sugar, produce lactate, lactate rewrites the behavior of immune cells and tumor cells through chemical tags, and the result is an environment that resists both the body's natural defenses and cancer drugs.
This system — called the glycolysis-lactylation axis — appears to operate across multiple cancer types, not just one. That breadth makes it a compelling research target.
That's Where Things Get Interesting
Researchers have identified several points in this chain that could potentially be disrupted. Drugs that block glycolytic enzymes (the proteins that help tumors burn sugar) could reduce lactate production. Drugs that block the transporters carrying lactate out of tumor cells could trap it inside. And drugs targeting the proteins that add or remove lactylation tags could reset the chemical messaging system.
Some of these approaches are already being studied alongside existing immunotherapy drugs.
Where This Fits in the Bigger Picture
Immunotherapy resistance is one of oncology's most pressing problems. Checkpoint inhibitors — the class of drugs that block PD-1 and PD-L1 — have transformed cancer care, but a substantial proportion of patients don't respond or eventually stop responding. If the lactylation pathway is a key driver of that resistance, targeting it could meaningfully expand who benefits from immunotherapy.
If you or a loved one is being treated with immunotherapy and it isn't working as hoped, this research offers a glimpse of why that might happen and what scientists are doing about it. But these approaches are not available as treatments today.
Talk to your oncologist about clinical trial options if current therapies aren't working. Researchers are actively looking for patients to help test the next generation of approaches.
The bulk of this evidence comes from laboratory models — cell cultures and animals — not from large human trials. The jump from promising lab results to effective human treatments is significant and often takes years or decades. Many approaches that work in preclinical settings don't survive clinical testing.
Researchers are calling for prospective clinical trials (studies that follow patients forward in time under controlled conditions) to test whether blocking the glycolysis-lactylation axis actually improves outcomes in cancer patients. If those trials succeed, combination strategies — pairing lactylation inhibitors with existing immunotherapy drugs — could eventually offer new options to patients who currently have none.
